Overview of Dr. Bott
Dr. Matthew Bott is a thoracic surgeon in Commack, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of Virginia School of Medicine and has been in practice 12 years. He is one of 40 doctors at Memorial Sloan Kettering Cancer Center and one of 7 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Thoracic Surgery. He has more than 100 publications and over 500 citings.
Office
650 Commack Road
Commack, NY 11725
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Thoracic Surgery, 2013 - 2015
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2005 - 2013
University of Virginia School of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2007 - 2025
MO State Medical License 2013 - 2015- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Start of enrollment: 2022 Oct 19
Roles: Contact
Publications & Presentations
PubMed
- 52 citationsA Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.Gregory D. Jones, Whitney S. Brandt, Ronglai Shen, Francisco Sanchez-Vega, Kay See Tan
JAMA Surgery. 2021-02-01 - 19 citationsPredictors of survival following surgical resection of limited-stage small cell lung cancerNicolas Zhou, Matthew J. Bott, Bernard J. Park, Eric Vallières, Candice L. Wilshire
The Journal of Thoracic and Cardiovascular Surgery. 2021-03-01 - 2 citationsThe BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.Hiroki Sato, Tatsuo Ito, Takuo Hayashi, Shigehisa Kitano, Hediye Erdjument-Bromage
Oncogene. 2024-04-01
Journal Articles
- A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung AdenocarcinomaMatthew J Bott, Daniela Molena, Prasad S Adusumilli, JAMA Surgery
Press Mentions
Surgical Outcomes After Neoadjuvant Chemotherapy plus Nivolumab with and Without Ipilimumab in Patients with Non-Small Cell Lung CancerMay 8th, 2023- Treatment of Esophageal/Gastroesophageal Junction Adenocarcinoma in Patients with History of Prior Bariatric SurgeryMay 7th, 2023
Kicking Pancreatic Cancer’s ButtSeptember 5th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
